HUTCHMED (NASDAQ:HCM - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Monday.
Separately, The Goldman Sachs Group increased their target price on HUTCHMED from $17.00 to $19.00 and gave the company a "neutral" rating in a research note on Thursday, August 1st.
Check Out Our Latest Research Report on HCM
HUTCHMED Stock Performance
HCM stock traded down $0.25 during midday trading on Monday, reaching $18.38. The company's stock had a trading volume of 65,870 shares, compared to its average volume of 123,215. The business's 50-day simple moving average is $18.67 and its 200-day simple moving average is $18.68. HUTCHMED has a 52 week low of $11.93 and a 52 week high of $21.92. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Institutional Trading of HUTCHMED
Hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. increased its holdings in shares of HUTCHMED by 638.2% in the third quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock worth $69,000 after acquiring an additional 3,057 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in HUTCHMED by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock worth $117,000 after purchasing an additional 2,321 shares in the last quarter. Rhumbline Advisers raised its holdings in HUTCHMED by 8.1% during the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock worth $129,000 after buying an additional 564 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of HUTCHMED in the second quarter valued at approximately $213,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in shares of HUTCHMED by 9.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company's stock worth $226,000 after acquiring an additional 1,168 shares during the period. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
